N@N

Joseph Schwartz Maintained (SRPT) at Buy with Increased Target to $126 on, Mar 2nd, 2021

Joseph Schwartz of SVB Leerink, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Increased Target from $125 to $126 on, Mar 2nd, 2021.

Joseph has made no other calls on SRPT in the last 4 months.

There are 9 other peers that have a rating on SRPT. Out of the 9 peers that are also analyzing SRPT, 5 agree with Joseph's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Joel Beatty of "Citigroup" Downgraded from Strong Buy to Hold and Held Target at $108 on, Tuesday, January 12th, 2021
• Colin Bristow of "UBS" Downgraded from Strong Buy to Hold on, Monday, January 11th, 2021
• Danielle Brill of "Raymond James" Downgraded from Buy to Hold on, Friday, January 8th, 2021
• Martin Auster of "Credit Suisse" Maintained at Hold with Decreased Target to $73 on, Friday, January 8th, 2021
• Matthew Harrison of "Morgan Stanley" Downgraded from Buy to Hold and Decreased Target to $95 on, Friday, January 8th, 2021

These are the ratings of the 4 analyists that currently disagree with Joseph

---

• Difei Yang of "Mizuho" Maintained at Strong Buy with Increased Target to $160 on, Friday, February 26th, 2021
• Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy and Held Target at $135 on, Friday, February 26th, 2021
• Anupam Rama of "JP Morgan" Downgraded from Buy to Sell and Held Target at $96 on, Friday, January 8th, 2021
• Chad Messer of "Needham" Maintained at Strong Buy with Decreased Target to $166 on, Friday, January 8th, 2021

Contributing Sources

---